(NASDAQ: VTYX) Ventyx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Ventyx Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VTYX's revenue for 2026 to be $6,539,704,186, with the lowest VTYX revenue forecast at $6,539,704,186, and the highest VTYX revenue forecast at $6,539,704,186. On average, 2 Wall Street analysts forecast VTYX's revenue for 2027 to be $3,362,553,166, with the lowest VTYX revenue forecast at $185,402,147, and the highest VTYX revenue forecast at $6,539,704,186.
In 2028, VTYX is forecast to generate $17,802,884,604 in revenue, with the lowest revenue forecast at $584,729,848 and the highest revenue forecast at $35,021,039,360.